ABVC BioPharma (ABVC) vs Telomir Pharmaceuticals (TELO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
ABVC BioPharma (ABVC) has outperformed Telomir Pharmaceuticals (TELO) over the past year, losing 67.8% versus a loss of 71.6%. Telomir Pharmaceuticals is the larger company by market cap ($26.8 million vs $23.4 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABVC | TELO |
|---|---|---|
| Share price | $0.8663 | $0.364 |
| Market cap | $23.37M | $26.82M |
| 1-day change | -1.56% | -17.24% |
| YTD return | -59.33% | -72.63% |
| 1-year return | -67.80% | -71.56% |
| 5-year return | -97.29% | — |
| EPS (TTM) | $-0.20 | $-0.96 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $296.00K | — |
| Revenue growth (YoY) | -41.91% | — |
| Net income (latest FY) | $-7.91M | $-10.41M |
| Operating margin | -2415.97% | — |
| Net margin | -2671.81% | — |
| 52-week high | $2.87 | $1.58 |
| 52-week low | $0.707 | $0.353 |
| Distance from 52-week high | -69.82% | -76.96% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +998.90% |
| Average volume | 81.92K | 126.14K |
| Shares outstanding | 26.98M | 73.68M |
| Employees | 16 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About ABVC BioPharma
ABVC stock →ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials as a combination therapy for triple negative breast cancer; ABV-1504, which has completed Phase II clinical trials for depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601, which is in Phase I/II clinical trials for treating depression in cancer patients.
Health Care · Biotechnology: Pharmaceutical Preparations · 16 employees
About Telomir Pharmaceuticals
TELO stock →Telomir Pharmaceuticals, Inc., a preclinical-stage biotechnology company, focuses on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases. It is developing Telomir-1, an oral small molecule metal ion regulator designed to protect against age-related conditions, including Wilson's disease, Type 2 diabetes, age-related macular degeneration (AMD), oncology, and epigenetic regulation, as well as Alzheimer's disease and Progeria.
Health Care · Biotechnology: Pharmaceutical Preparations
ABVC vs TELO FAQ
Which is bigger, ABVC BioPharma or Telomir Pharmaceuticals?
Telomir Pharmaceuticals (TELO) is larger, with a market capitalization of $26.82M compared with $23.37M for ABVC BioPharma (ABVC).
Which stock has performed better over the past year, ABVC or TELO?
ABVC returned -67.80% over the past 12 months, compared with -71.56% for TELO (price return, excluding dividends). Past performance does not predict future results.
Are ABVC BioPharma and Telomir Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.